52
Participants
Start Date
August 2, 2019
Primary Completion Date
January 17, 2025
Study Completion Date
January 17, 2025
Methotrexate
Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
Ondansetron
"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
Folic/folinic acid
Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
University of Calgary / Alberta Children's Hospital, Calgary
University of Alberta, Edmonton
BC Children's Hospital, Vancouver
University of Manitoba/Children's hospital research institute, Winnipeg
McMaster University/McMaster Children's Hospital, Hamilton
London Health Sciences Centre, London
Hospital for Sick Children, Toronto
McGill University Health Centre, Montreal
Université de Montréal, Montreal
Royal University Hospital, Saskatoon
CHU de Quebec - Universite Laval, Québec
Collaborators (1)
The Arthritis Society, Canada
OTHER
University of Calgary
OTHER
The Hospital for Sick Children
OTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
London Health Sciences Centre
OTHER
University of Manitoba
OTHER
Alberta Children's Hospital
OTHER
McMaster University
OTHER
McMaster Children's Hospital
OTHER
Université de Montréal
OTHER
University of British Columbia
OTHER